The US FDA has formally accepted SK Life Science Inc.’s new drug application (NDA) for cenobamate, the Korean firm's investigational antiepileptic for the treatment of partial-onset seizures in adults, paving the way for the company's goal of bringing to market an effective therapy for drug-resistant epilepsy, seen as the most pressing unmet medical need in this segment.
Cenobamate (YKP3089), discovered and developed by SK Biopharmaceuticals Co. Ltd
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?